Literature DB >> 29398467

Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report.

Sri Lakshmi Hyndavi Yeruva1, Mehrbod Som Javadi2, Vered Stearns3.   

Abstract

Entities:  

Keywords:  Biomarkers; CDK inhibitors; Complete response; Metastatic breast cancer; Palbociclib

Mesh：

Substances：

Year:  2017        PMID： 29398467      PMCID： PMC5970002          DOI： 10.1016/j.clbc.2017.12.008

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN： 1526-8209            Impact factor:   3.225


× No keyword cloud information.
  15 in total

Review 1.  Chemotherapeutic Strategies for advanced breast cancer.

Authors:  Susanne Briest; Vered Stearns
Journal:  Oncology (Williston Park)       Date:  2007-10       Impact factor: 2.990

2.  FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.

Authors:  Amanda J Walker; Suparna Wedam; Laleh Amiri-Kordestani; Erik Bloomquist; Shengui Tang; Rajeshwari Sridhara; Wei Chen; Todd R Palmby; Jeanne Fourie Zirkelbach; Wentao Fu; Qi Liu; Amy Tilley; Geoffrey Kim; Paul G Kluetz; Amy E McKee; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2016-07-12       Impact factor: 12.531

3.  Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers.

Authors:  Mehrdad Nadji; Carmen Gomez-Fernandez; Parvin Ganjei-Azar; Azorides R Morales
Journal:  Am J Clin Pathol       Date:  2005-01       Impact factor: 2.493

4.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

Authors:  George W Sledge; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; Martin Frenzel; Yong Lin; Susana Barriga; Ian C Smith; Nawel Bourayou; Antonio Llombart-Cussac
Journal:  J Clin Oncol       Date:  2017-06-03       Impact factor: 44.544

Review 5.  Cyclin-dependent kinase pathways as targets for cancer treatment.

Authors:  Geoffrey I Shapiro
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

6.  CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.

Authors:  Angela DeMichele; Amy S Clark; Kay See Tan; Daniel F Heitjan; Kristi Gramlich; Maryann Gallagher; Priti Lal; Michael Feldman; Paul Zhang; Christopher Colameco; David Lewis; Melissa Langer; Noah Goodman; Susan Domchek; Keerthi Gogineni; Mark Rosen; Kevin Fox; Peter O'Dwyer
Journal:  Clin Cancer Res       Date:  2014-12-11       Impact factor: 12.531

7.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Authors:  Richard S Finn; Judy Dering; Dylan Conklin; Ondrej Kalous; David J Cohen; Amrita J Desai; Charles Ginther; Mohammad Atefi; Isan Chen; Camilla Fowst; Gerret Los; Dennis J Slamon
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

Review 8.  FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.

Authors:  Julia A Beaver; Laleh Amiri-Kordestani; Rosane Charlab; Wei Chen; Todd Palmby; Amy Tilley; Jeanne Fourie Zirkelbach; Jingyu Yu; Qi Liu; Liang Zhao; Joyce Crich; Xiao Hong Chen; Minerva Hughes; Erik Bloomquist; Shenghui Tang; Rajeshwari Sridhara; Paul G Kluetz; Geoffrey Kim; Amna Ibrahim; Richard Pazdur; Patricia Cortazar
Journal:  Clin Cancer Res       Date:  2015-08-31       Impact factor: 12.531

9.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Authors:  Massimo Cristofanilli; Nicholas C Turner; Igor Bondarenko; Jungsil Ro; Seock-Ah Im; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Ke Zhang; Kathy Puyana Theall; Yuqiu Jiang; Cynthia Huang Bartlett; Maria Koehler; Dennis Slamon
Journal:  Lancet Oncol       Date:  2016-03-03       Impact factor: 41.316

10.  Palbociclib and Letrozole in Advanced Breast Cancer.

Authors:  Richard S Finn; Miguel Martin; Hope S Rugo; Stephen Jones; Seock-Ah Im; Karen Gelmon; Nadia Harbeck; Oleg N Lipatov; Janice M Walshe; Stacy Moulder; Eric Gauthier; Dongrui R Lu; Sophia Randolph; Véronique Diéras; Dennis J Slamon
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.